

# Stanford

---



## Jay Michael S. Balagtas

Clinical Associate Professor, Pediatrics - Hematology & Oncology

### CLINICAL OFFICES

- **Oncology**

1000 Welch Rd Ste 300

Palo Alto, CA 94304

Tel (650) 723-5535      Fax (650) 723-5231

- **John Muir Medical Center Pediatric Hematology Oncology**

1601 Ygnacio Valley Rd 3E

Walnut Creek, CA 94598-3122

Tel (925) 941-4144      Fax (925) 947-3208

- **California Pacific Medical Center**

1100 Van Ness Ave

7th Fl

San Francisco, CA 94109

Tel (844) 733-2762      Fax (650) 725-7578

### Bio

---

### CLINICAL FOCUS

- Ped Hematology/Oncology
- Pediatric Hematology-Oncology

### ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Pediatrics - Hematology & Oncology

### PROFESSIONAL EDUCATION

- Fellowship: Stanford University Pediatric Hematology Oncology Fellowship (2009) CA
- Residency: United States Naval Medical Center San Diego Pediatric Residency (2003) CA
- Medical Education: New York Medical College Registrar (1998) NY
- Board Certification: Pediatric Hematology-Oncology, American Board of Pediatrics (2011)
- Board Certification: Pediatrics, American Board of Pediatrics (2003)

## Research & Scholarship

---

### CLINICAL TRIALS

- A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia, Recruiting
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia, Recruiting
- Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors, Recruiting
- Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement, Recruiting
- Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors, Recruiting
- Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery, Recruiting
- Combination Chemotherapy With or Without Temozolomide in Treating Patients With Intermediate Risk Rhabdomyosarcoma, Recruiting
- Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors, Recruiting
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, Recruiting
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy, Recruiting
- Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia, Recruiting
- Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma, Recruiting
- Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies, Recruiting
- Neuropsychological and Behavioral Testing in Younger Patients With Cancer, Recruiting
- Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas, Recruiting
- Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma, Recruiting
- Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome, Recruiting
- Study of Kidney Tumors in Younger Patients, Recruiting
- Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors, Recruiting
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial), Recruiting
- Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia, Recruiting
- Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations, Recruiting
- Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours, Not Recruiting
- Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia, Not Recruiting
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors, Not Recruiting
- Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET, Not Recruiting
- Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma, Not Recruiting
- Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma, Not Recruiting
- Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma, Not Recruiting
- Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL), Not Recruiting
- Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma, Not Recruiting

- Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma, Not Recruiting
- Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder, Not Recruiting
- Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial), Not Recruiting
- Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer, Not Recruiting

## Publications

---

### PUBLICATIONS

- **A challenging case of recurrent idiopathic hemophagocytic lymphohistiocytosis (HLH) initially presenting in an infant with *Pneumocystis jirovecii* pneumonia**  
Solomon, B., Balagtas, J., Chien, M., Pooni, R., Balboni, I., Weinacht, K., Gernez, Y.  
SPRINGER/PLENUM PUBLISHERS.2021: S55
- **P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs).**  
Subramaniam, S., Toner, G. C., Stockler, M. R., Martin, A., Pashankar, F. D., Tran, B., Jeffery, M., Mazhar, D., Huddart, R. A., Walpole, E., Stevanovic, A., Wyld, D., Hanning, et al  
LIPPINCOTT WILLIAMS & WILKINS.2021
- **The identification of at-risk patients and prevention of venous thromboembolism in pediatric cancer: guidance from the SSC of the ISTH *JOURNAL OF THROMBOSIS AND HAEMOSTASIS***  
Tullius, B. P., Athale, U., Van Ommen, C. H., Chan, A. C., Palumbo, J. S., Balagtas, J. S., Subcomm Hemostasis & Malignan, Subcomm Pediat Neonatal Throm  
2018; 16 (1): 175–80
- **Rate of abnormal vaginal bleeding and contraception counseling in women undergoing chemotherapy *JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY***  
Cutler, K. E., Creinin, M. D., Balagtas, J. S., Hou, M. Y.  
2016; 14 (8): 337–41
- **Subcutaneous Panniculitis-Like T-Cell Lymphoma: Pediatric Case Series Demonstrating Heterogeneous Presentation and Option for Watchful Waiting *PEDIATRIC BLOOD & CANCER***  
Johnston, E. E., LeBlanc, R. E., Kim, J., Chung, J., Balagtas, J., Kim, Y. H., Link, M. P.  
2015; 62 (11): 2025-2028
- **Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types. *PLoS genetics***  
Giacomini, C. P., Sun, S., Varma, S., Shain, A. H., Giacomini, M. M., Balagtas, J., Sweeney, R. T., Lai, E., Del Vecchio, C. A., Forster, A. D., Clarke, N., Montgomery, K. D., Zhu, et al  
2013; 9 (4)
- **Therapeutic Complications in a Patient With High-Risk Acute Lymphoblastic Leukemia and Undiagnosed Hereditary Hemochromatosis *PEDIATRIC BLOOD & CANCER***  
Balagtas, J. M., Dahl, G. V.  
2012; 58 (1): 101-103
- **Liposomal amphotericin B associated with severe hyperphosphatemia *PEDIATRIC INFECTIOUS DISEASE JOURNAL***  
Sutherland, S. M., Hong, D. K., Balagtas, J., Gutierrez, K., Dvorak, C. C., Sarwal, M.  
2008; 27 (1): 77-79